Bifidobacterium Adolescentis Supplementation for Elderly Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Low-grade inflammation, characterized by elevated levels of C-reactive protein (CRP) and TNF-α, is prevalent in the elderly population, increasing the risk of cardiovascular disease, type 2 diabetes, rheumatoid arthritis, and cancer, and is associated with a decline in Bifidobacterium adolescentis abundance with age.
Innovation Solution
Supplementation with Bifidobacterium adolescentis DSM 29103, administered at therapeutically effective doses of 1 billion CFU or greater per day, to modulate elevated levels of CRP and TNF-α through dietary manipulation, using probiotic products like capsules, tablets, or dairy products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If Bifidobacterium adolescentis supplementation is administered to elderly subjects, then inflammation markers (hs-CRP and TNF-α levels) are reduced, but the complexity of probiotic formulation and administration increases
Solution Approach 1:
The patent utilizes single-use probiotic formulations containing B. adolescentis that are administered as discrete units (capsules or dietary supplements). Each formulation is designed for short-term stability outside the body, eliminating the need for complex storage infrastructure while delivering the therapeutic effect. This approach reduces inflammation markers without requiring long-term storage facilities or complex delivery systems.
2Object-affected harmful factors
If high doses of Bifidobacterium adolescentis (10 billion CFU) are administered, then anti-inflammatory effects are enhanced, but the cost and complexity of supplementation increases
Solution Approach 1:
The patent systematically evaluates different dosing parameters (1 billion CFU vs 10 billion CFU daily) to determine the optimal balance between therapeutic effect and practical considerations. By varying the CFU dosage parameter, the study identifies that both doses reduce inflammation markers in elderly subjects, allowing selection based on individual needs, cost constraints, and formulation stability requirements rather than mandating the highest dose.
3Object-affected harmful factors
If Bifidobacterium adolescentis supplementation is implemented in elderly population, then health outcomes are improved, but the difficulty of ensuring adequate intake and compliance increases
Solution Approach 1:
The patent describes probiotic formulations that are designed to be self-administered by elderly subjects without requiring complex preparation or storage conditions. The capsules or dietary supplements are formulated for stability at ambient temperatures and do not require refrigeration, allowing subjects to independently maintain their supplementation regimen. This self-service approach improves compliance by eliminating barriers related to storage complexity and preparation requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Alleviates low-grade inflammation by reducing CRP and TNF-α levels, potentially improving health outcomes and maintaining a healthy gastrointestinal microbial community in the elderly.
Implementation Method 1
Bifidobacteria interact with key elements of intestinal functioning and contribute to maintaining homeostasis. Recentscientific progress has demonstrated that bifidobacteria, through strain-dependent interactions with the host may reduce mucosal antigen load, improve the intestinal barrier, and induce regulation of local and systemic immune responses.
Data Source
AI summary
The present invention generally relates to human therapeutic effects of Bifidobacterium adolescentis, and particularly alleviating of low-grade inflammation in an elderly population.